Skip to main content

Table 4 Antibiotic and multidrug resistance of the UPEC’s isolates, n (%)

From: An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study

Antibiotics Total isolates, n = 110 (%) MDR, n = 70 (%) Male, n = 24 (%) Female, n = 86 (%) *p Hospital-acquired, n = 31 (%) Community-acquired, n = 79 (%) *p
Amikacin 11 (10.0) 11 (15.9) 4 (16.7) 7 (8.1)   1 (3.2) 10 (12.7)  
Gentamicin 31 (28.2) 29 (41.4) 11 (45.8) 20 (23.3) 0.0297 10 (32.3) 21 (26.6)  
Tobramycin 21 (19.1) 21 (30.0) 10 (41.7) 11 (12.8) 0.0015 9 (29.0) 12 (15.2)  
Netilmicin 6 (5.5) 5 (7.1) 2 (8.3) 4 (4.7)   2 (6.5) 4 (5.1)  
Ampicillin 78 (70.9) 60 (85.7) 20 (83.3) 58 (67.4)   24 (77.4) 54 (68.4)  
Ampicillin–sulbactam 61 (55.5) 54 (77.1) 15 (62.5) 46 (53.5)   18 (58.1) 43 (54.4)  
Amoxicillin–clavulanic acid 26 (23.6) 23 (32.9) 5 (20.8) 21 (24.4)   6 (19.4) 20 (25.3)  
Piperacillin–tazobactam 61 (55.5) 54 (77.1) 15 (62.5) 46 (53.5)   18 (58.1) 43 (54.4)  
Cefazolin 46 (41.8) 45 (64.3) 15 (62.5) 31 (36.0) 0.0202 16 (51.6) 30 (38.0)  
Cefotaxime 20 (18.2) 20 (28.6) 5 (20.8) 15 (17.4)   6 (19.4) 14 (17.7)  
Ceftazidime 27 (24.5) 27 (38.6) 13 (54.2) 14 (16.3) 0.0001 12 (38.7) 15 (19.0) 0.0306
Ceftriaxone 30 (27.3) 30 (42.9) 14 (58.3) 16 (18.6) 0.0001 13 (41.9) 17 (21.5) 0.0305
Cefepime 29 (26.4) 29 (41.4) 14 (58.3) 15 (17.4) 0.0001 12 (38.7) 17 (21.5)  
Trimethoprim–sulfamethoxazole 80 (72.7) 59 (84.3) 18 (75.0) 62 (72.1)   24 (77.4) 56 (70.9)  
Ciprofloxacin 52 (47.3) 49 (70.0) 17 (70.8) 35 (40.7) 0.0089 15 (48.4) 37 (46.8)  
Levofloxacin 48 (43.6) 45 (64.3) 16 (66.7) 32 (37.2) 0.0314 13 (41.9) 35 (44.3)  
Norfloxacin 18 (16.4) 18 (25.7) 3 (12.5) 15 (17.4)   2 (6.5) 16 (20.3)  
Nitrofurantoin 14 (12.7) 12 (17.1) 5 (20.8) 9 (10.5)   4 (12.9) 10 (12.7) 0.0002
Ertapenem 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)   0 (0.0) 0 (0.0)  
Imipenem 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)   0 (0.0) 0 (0.0)  
  1. * Only statistical significant values are shown